乳腺癌术后上肢淋巴水肿的研究进展

doi:10.3969/j.issn.1004-616x.2025.03.014

摘要/Abstract

摘要： 乳腺癌术后上肢淋巴水肿(BCRL)是乳腺癌手术严重的并发症之一，明确其发病机制对于制定相应的防治策略具有重要意义。BCRL的发病机制包括上肢淋巴回流受阻、炎症反应、离子通道功能障碍等，同时受放化疗等多种因素影响。BCRL的预防主要包括早期宣教及康复训练、逆向腋窝淋巴显影、上肢淋巴系统识别保留技术、显微外科预防性淋巴修复。其治疗包括手术及非手术治疗两种方式，其中手术治疗包括病变组织清除术、淋巴静脉旁路手术、自体带血管淋巴结移植术；非手术治疗包括综合消肿治疗、光生物调节治疗、间歇充气压缩泵治疗。新兴的细胞治疗有望摆脱传统疗法需要长期治疗等缺点，具有独特的优势。随着BCRL发生机制的深入研究，更多的防治策略将不断出现并逐步完善，使BCRL的防治趋于规范化。本文对近年来BCRL的发病机制、预防和治疗等方面的研究进展进行了综述。

关键词: 乳腺癌, 术后上肢淋巴水肿, 淋巴回流受阻, 逆向腋窝淋巴显影, 综合消肿治疗

中图分类号:

R737.9

詹婉琳, 邱梓旋, 林芸, 邱斯奇, 吴智勇. 乳腺癌术后上肢淋巴水肿的研究进展[J]. 癌变·畸变·突变, 2025, 37(3): 257-261.

参考文献

[1] 刘兆喆, 李秋华, 李文雅, 等. 乳腺癌术后淋巴水肿中西医结合诊治中国专家共识[J]. 创伤与急危重病医学, 2023, 11(1): 1-8.
[2] GÄRTNER R, MEJDAHL M K, ANDERSEN K G, et al. Development in self-reported arm-lymphedema in Danish women treated for early-stage breast cancer in 2005 and 2006: a nationwide follow-up study[J]. Breast, 2014, 23(4): 445-452.
[3] KIBAR S, DALYAN ARAS M, ÜNSAL DELIALIOĞLU S. The risk factors and prevalence of upper extremity impairments and an analysis of effects of lymphoedema and other impairments on the quality of life of breast cancer patients[J]. Eur J Cancer Care, 2017, 26(4). DOI: 10.1111/ ecc.12433.
[4] WETZIG N, GILL P G, ZANNINO D, et al. Sentinel lymph node based management or routine axillary clearance? Three-year outcomes of the RACS sentinel node biopsy versus axillary clearance (SNAC) 1 trial[J]. Ann Surg Oncol, 2015, 22(1): 17-23.
[5] FU M R. Breast cancer-related lymphedema: symptoms, diagnosis, risk reduction, and management[J]. World J Clin Oncol, 2014, 5(3): 241- 247.
[6] RUPP J, HADAMITZKY C, HENKENBERENS C, et al. Frequency and risk factors for arm lymphedema after multimodal breast-conserving treatment of nodal positive breast Cancer - a long-term observation[J]. Radiat Oncol, 2019, 14(1): 39.
[7] 李喆, 葛海燕. 乳腺癌根治术后上肢淋巴水肿的研究进展[J]. 中华乳腺病杂志: 电子版, 2012, 6(2): 201-208.
[8] STANTON A W B, MODI S, BENNETT BRITTON T M, et al. Lymphatic drainage in the muscle and subcutis of the arm after breast cancer treatment[J]. Breast Cancer Res Treat, 2009, 117(3): 549-557.
[9] BATES D O. The chronic effect of vascular endothelial growth factor on individually perfused frog mesenteric microvessels[J]. J Physiol, 1998, 513(Sup 1): 225-233.
[10] ZAMPELL J C, YAN A L, ELHADAD S, et al. CD4⁺ cells regulate fibrosis and lymphangiogenesis in response to lymphatic fluid stasis[J]. PLoS One, 2012, 7(11): e49940.
[11] AVRAHAM T, ZAMPELL J C, YAN A L, et al. Th2 differentiation is necessary for soft tissue fibrosis and lymphatic dysfunction resulting from lymphedema[J]. FASEB J, 2013, 27(3): 1114-1126.
[12] VON DER WEID P Y, RAHMAN M, IMTIAZ M S, et al. Spontaneous transient depolarizations in lymphatic vessels of the guinea pig mesentery: pharmacology and implication for spontaneous contractility [J]. Am J Physiol Heart Circ Physiol, 2008, 295(5): H1989-H2000.
[13] SENATORE A, GUAN W, SPAFFORD J D. Cav3 T-type channels: regulators for gating, membrane expression, and cation selectivity[J]. Pflugers Arch, 2014, 466(4): 645-660.
[14] DISIPIO T, RYE S, NEWMAN B, et al. Incidence of unilateral arm lymphoedema after breast cancer: a systematic review and meta-analysis [J]. Lancet Oncol, 2013, 14(6): 500-515.
[15] HINRICHS C S, WATROBA N L, REZAISHIRAZ H, et al. Lymphedema secondary to postmastectomy radiation: incidence and risk factors[J]. Ann Surg Oncol, 2004, 11(6): 573-580.
[16] NORMAN S A, LOCALIO A R, KALLAN M J, et al. Risk factors for lymphedema after breast cancer treatment[J]. Cancer Epidemiol Biomark Prev, 2010, 19(11): 2734-2746.
[17] VETTO J T. Lymphedema after breast cancer treatment-not just the surgeon’s fault[J]. JAMA Surg, 2019, 154(9): 810.
[18] FERGUSON C M, SWAROOP M N, HORICK N, et al. Impact of ipsilateral blood draws, injections, blood pressure measurements, and air travel on the risk of lymphedema for patients treated for breast cancer [J]. J Clin Oncol, 2016, 34(7): 691-698.
[19] HASENOEHRL T, PALMA S, RAMAZANOVA D, et al. Resistance exercise and breast cancer-related lymphedema-a systematic review update and meta-analysis[J]. Support Care Cancer, 2020, 28(8): 3593- 3603.
[20] ABDELHAMID M I, BARI A A, FARID M I, et al. Evaluation of axillary reverse mapping (ARM) in clinically axillary node negative breast cancer patients-Randomised controlled trial[J]. Int J Surg, 2020, 75: 174-178.
[21] PASKO J L, GARREAU J, CARL A, et al. Axillary reverse lymphatic mapping reduces patient perceived incidence of lymphedema after axillary dissection in breast cancer[J]. Am J Surg, 2015, 209(5): 890-895.
[22] YUAN Q Q, WU G S, XIAO S Y, et al. Identification and preservation of arm lymphatic system in axillary dissection for breast cancer to reduce arm lymphedema events: a randomized clinical trial[J]. Ann Surg Oncol, 2019, 26(11): 3446-3454.
[23] BOCCARDO F M, CASABONA F, FRIEDMAN D, et al. Surgical prevention of arm lymphedema after breast cancer treatment[J]. Ann Surg Oncol, 2011, 18(9): 2500-2505.
[24] BOZKURT M, PALMER L J, GUO Y. Effectiveness of decongestive lymphatic therapy in patients with lymphedema resulting from breast cancer treatment regardless of previous lymphedema treatment[J]. Breast J, 2017, 23(2): 154-158.
[25] BAXTER G D, LIU L Z, TUMILTY S, et al. Low level laser therapy for the management of breast cancer-related lymphedema: a randomized controlled feasibility study[J]. Lasers Surg Med, 2018, 50(9): 924-932.
[26] SZUBA A, ACHALU R, ROCKSON S G. Decongestive lymphatic therapy for patients with breast carcinoma-associated lymphedema. A randomized, prospective study of a role for adjunctive intermittent pneumatic compression[J]. Cancer, 2002, 95(11): 2260-2267.
[27] 霍永平, 阎丽婷, 夏利敏, 等. 地奥司明联合负压淋巴回流治疗乳腺癌术后上肢淋巴水肿疗效分析[J]. 中国现代普通外科进展, 2021, 24(4): 296-298.
[28] 齐雪, 杨秀, 关红丹. 地奥司明联合己酮可可碱治疗乳腺癌术后患侧上肢淋巴水肿的临床效果[J]. 临床合理用药, 2024, 17(18): 136-138.
[29] 胡书源, 柳弥. 乳腺癌上肢淋巴水肿的研究进展[J]. 肿瘤预防与治疗, 2021, 34(3): 262-268.
[30] 郝昆, 孙宇光, 王仁贵, 等. 抽吸减容术治疗乳腺癌术后上肢淋巴水肿[J]. 组织工程与重建外科, 2024, 20(1): 69-74, 82.
[31] DAMSTRA R J, VOESTEN H M, KLINKERT P, et al. Circumferential suction-assisted lipectomy for lymphoedema after surgery for breast cancer[J]. Br J Surg, 2009, 96(8): 859-864.
[32] PHILLIPS G S A, GORE S, RAMSDEN A, et al. Lymphaticovenular anastomosis improves quality of life and limb volume in patients with secondary lymphedema after breast cancer treatment[J]. Breast J, 2019, 25(5): 859-864.
[33] 中华医学会整形外科学分会淋巴水肿治疗学组. 乳腺癌术后上肢淋巴水肿诊治指南与规范(2021年版)[J]. 组织工程与重建外科, 2021, 17(6): 457-461.
[34] SCHAVERIEN M V, BADASH I, PATEL K M, et al. Vascularized lymph node transfer for lymphedema[J]. Semin Plast Surg, 2018, 32(1): 28-35.
[35] MOUSAVI S R, AKBARI M E, ZARRINTAN S. Vascularized gastroepiploic lymph node transfer significantly improves breast cancer-related lymphedema[J]. J Surg Oncol, 2020, 121(1): 163-167.
[36] FORTE A J, HUAYLLANI M T, BOCZAR D, et al. Lipoaspiration and lymph node transfer for treatment of breast cancer-related lymphedema: a systematic review[J]. Cureus, 2019, 11(11): e6096.
[37] LEPPÄPUSKA I M, SUOMINEN E, VIITANEN T, et al. Combined surgical treatment for chronic upper extremity lymphedema patients: simultaneous lymph node transfer and liposuction[J]. Ann Plast Surg, 2019, 83(3): 308-317.
[38] ZHOU H, WANG M, HOU C Q, et al. Exogenous VEGF-C augments the efficacy of therapeutic lymphangiogenesis induced by allogenic bone marrow stromal cells in a rabbit model of limb secondary lymphedema [J]. Jpn J Clin Oncol, 2011, 41(7): 841-846.
[39] MALDONADO G E M, PÉREZ C A A, COVARRUBIAS E E A, et al. Autologous stem cells for the treatment of post-mastectomy lymphedema: a pilot study[J]. Cytotherapy, 2011, 13(10): 1249-1255.